Inventiva, a clinical-stage biopharmaceutical company, announced preliminary financial results for the first half of 2026, reporting €166.1 million in cash and cash equivalents and €67.8 million in short-term deposits as of June 30, 2026. The company used €48.7 million in operating activities, mainly due to advancing its Phase 3 clinical trial for MASH treatment. No revenues were recorded in H1 2026, compared to €4.5 million in H1 2025. With recent equity and debt financing completed in June 2026, Inventiva expects to fund operations until the end of Q2 2027, potentially extending to early 2028 if additional financing milestones are met. The company continues to focus on developing lanifibranor, an oral therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Guangzhou's Nansha District is rapidly advancing as a global cross-border trade hub with its state-of-the-art automated container terminal and integrated multimodal transport system. In 2025, Nansha Port handled over 22.6 million TEUs and operates 18...
Nord Precious Metals Mining Inc., focused on high-grade silver mining in Northern Ontario, announced that CEO Frank J. Basa will present live at the OTCQB Virtual Investor Conference on August 5, 2026. The event allows investors to engage directly wi...
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, effective August 6, 2026. Distribution rates vary widely across ETFs, reflecting different investment strategies and associated risks, including semiconductor, AI, crypto, metals, an...
The global military drone market is expected to grow from $16.5 billion in 2025 to $42.8 billion by 2035, at a CAGR of 10%. Growth is fueled by AI-powered autonomous systems, defense modernization, and rising demand for surveillance, electronic warfa...
Man Group PLC has disclosed a 1.66% interest in Senior Plc's ordinary shares, totaling 6,962,764 shares, held through cash-settled derivatives as of August 3, 2026. The stake was increased by 104,804 shares via an equity swap transaction priced at ap...
